Journal Logo

Articles by R. Abonour

EVOLVING TREATMENT PATTERNS IN MULTIPLE MYELOMA (MM) DIFFER BY AGE AND REGION: ANALYSIS FROM INSIGHT MM, A GLOBAL, PROSPECTIVE, OBSERVATIONAL STUDY: PF601

Chari, A.; Weisel, K. C.; Usmani, S. Z.; More

HemaSphere. 3:254, June 2019.

TREATMENT CHOICES AND OUTCOMES FOR PATIENTS WITH MULTIPLE MYELOMA AFTER RELAPSE ON LENALIDOMIDE MAINTENANCE THERAPY: RESULTS FROM THE CONNECT® MM REGISTRY: PS1384

Jagannath, S.; Narang, M.; Ailawadhi, S.; More

HemaSphere. 3:634, June 2019.

COMPARATIVE EFFECTIVENESS OF TRIPLETS CONTAINING BORTEZOMIB (B), CARFILZOMIB (C), DARATUMUMAB (D), OR IXAZOMIB (I) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN ROUTINE CARE IN THE US: PS1419

Davies, F.; Rifkin, R.; Costello, C.; More

HemaSphere. 3:652-653, June 2019.